Table 1.
Patient | Sex | Age (yr) | Liver biopsy | Complica -tions | HBV DNA (pg/mL )1 | LAM3 (wk) | YMDD |
1 | F | 77 | Cirrhosis | HCC | 8 | 96 | M204I |
2 | M | 40 | CAH Ishak 9;2 | 2 | 156 | M204V | |
3 | M | 63 | Cirrhosis | Undetectable2 | 188 | M204V | |
4 | F | 68 | Cirrhosis | F2 esoph varices | 1600 | 44 | M204I |
5 | M | 55 | Cirrhosis | Undetectable2 | 104 | M204V, L180M | |
6 | F | 58 | Cirrhosis | 450 | 88 | WT | |
7 | M | 68 | Cirrhosis | F2 esoph varices | 64 | 76 | WT |
8 | M | 57 | CAH Ishak 7; 4 | 162 | 116 | WT | |
9 | M | 65 | Cirrhosis | 78 | 88 | WT | |
10 | M | 58 | Cirrhosis | 0.2 | 52 | WT | |
11 | F | 75 | Cirrhosis | 3.100 | 116 | WT |
Basal HBV DNA (Digene Capture 2 Assay, sensitivity 0.2 pg/mL, equal to 105 copies/mL) before starting lamivudine;
Sample taken after ALT flare;
Duration of lamivudine treatment before starting tenofovir; esoph: esophageal.